ArticleJournal of clinical microbiology2003
C6 test as an indicator of therapy outcome for patients with localized or disseminated lyme borreliosis.
Article in Journal of clinical microbiology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 44 citations in OpenAlex.
- Pre-treatment and post-treatment assessment of the C(6) test in patients with persistent symptoms and a history of Lyme borreliosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2004Trial
- Quantitative multiplexed strategies for human Lyme disease serological testing.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Subacute transverse myelitis with optic symptoms in neuroborreliosis: a case report.BMC neurology · 2020Article
- Laboratory diagnosis of Lyme disease: advances and challenges.Infectious disease clinics of North America · 2015Review
- A prospective study among patients presenting at the general practitioner with a tick bite or erythema migrans in The Netherlands.PloS one · 2013Article
- Dynamic longitudinal antibody responses during Borrelia burgdorferi infection and antibiotic treatment of rhesus macaques.Clinical and vaccine immunology : CVI · 2012Article
- Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection.PloS one · 2012Article
- Multiplex immunoassay for Lyme disease using VlsE1-IgG and pepC10-IgM antibodies: improving test performance through bioinformatics.Clinical and vaccine immunology : CVI · 2011Article
- Rapid, simple, quantitative, and highly sensitive antibody detection for lyme disease.Clinical and vaccine immunology : CVI · 2010Article
- Borrelia burgdorferi VlsE antigen for the serological diagnosis of Lyme borreliosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2008Article
- Quantitative measurement of C6 antibody following antibiotic treatment of Borrelia burgdorferi antibody-positive nonclinical dogs.Clinical and vaccine immunology : CVI · 2008Article
- Comparison of an automated Borrelia indirect chemiluminescent immunoassay (CLIA) with a VlsE/C6 ELISA and Immunoblot.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2007Article
- A decrease in the immunoglobulin G antibody response against the VlsE protein of Borrelia burgdorferi sensu lato correlates with the resolution of clinical signs in antibiotic-treated patients with early Lyme disease.Clinical and vaccine immunology : CVI · 2006Article
- A decline in C6 antibody titer occurs in successfully treated patients with culture-confirmed early localized or early disseminated Lyme Borreliosis.Clinical and diagnostic laboratory immunology · 2005Article
- Diagnosis of lyme borreliosis.Clinical microbiology reviews · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Management of Lyme disease would benefit from a test to assess therapy outcome. Such a test could be employed to ascertain if treatment of early Lyme disease was successful and would be helpful to clinicians assessing patients with lingering posttreatment symptoms. We reported recently that levels of the antibody to C(6), a Borrelia burgdorferi-derived peptide that is used as an antigen in the C(6)-Lyme diagnostic test, declined after successful antibiotic treatment of Lyme borreliosis patients. We assessed retrospectively the change in anti-C(6) antibody titers in 131 patients with either early localized disease (erythema migrans) or disseminated disease. All of these patients were treated with antibiotics and were free of the clinical signs shown at presentation within 12 weeks after the initiation of treatment. Decreases in reciprocal geometric mean titers (rGMT) of the anti-C(6) antibody were quantified for the subpopulation of 45 patients whose baseline rGMT were >/=80 and whose second serum specimens were obtained at least 6 months after the baseline specimen. Eighty percent of this patient group (36 of 45) experienced a >/=4-fold decrease in their rGMT (P < 0.0003). These results suggest that a change in the anti-C(6) antibody titer may serve as an indicator of therapy outcome for patients with localized or disseminated Lyme borreliosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.